Study record · Zenagamtide
Subcutaneous amycretin/zenagamtide Phase 1b/2a obesity study
Estimated mean body-weight change included -24.3% at 60 mg vs -1.1% placebo at week 36; lower-dose groups also showed substantial loss.
Key result
Estimated mean body-weight change included -24.3% at 60 mg vs -1.1% placebo at week 36; lower-dose groups also showed substantial loss.
Study details
Study designRandomized controlled early-phase study
PhasePhase 1b/2a
PopulationAdults with overweight or obesity
Sample size125
RouteSubcutaneous
Regimen / exposureMultiple once-weekly dose groups including 1.25, 5, 20 and 60 mg
Duration20–36 weeks depending on study part
ComparatorPlacebo
Primary endpoint / questionSafety/PK and relative body-weight change
Safety resultGI treatment-emergent AEs common; many withdrawals, including substantial discontinuation for reasons unrelated to AEs.
Key limitationsSmall early-phase parts, different durations/doses, high attrition; not directly comparable with mature Phase 3 obesity trials.
Registry / identifierNCT06064006